Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Takeda patent claims compounds that inhibit somatostatin receptor binding

July 13, 2004

Nonsteroidal modulators of farnesoid X receptors described in patent literature

July 13, 2004

Positive data, revised phase III plans for naveglitazar

July 13, 2004

AstraZeneca describes glucokinase activators

July 12, 2004

Glucose-lowering effects of liraglutide in patients with type 2 diabetes

July 12, 2004

AstraZeneca describes glucokinase activators

July 9, 2004

Nebido completes European mutual recognition procedure

July 9, 2004

Phase III study shows benefit of Bonviva/Boniva injection at extended intervals

July 9, 2004

Nycomed terminates Oxygent license agreement

July 9, 2004

Novel DPP-IV inhibitors claimed by Boehringer Ingelheim

July 8, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...